# Keros Therapeutics, Inc. (KROS) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Keros Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/KROS/mda/fy2025/): filed 2026-03-04; accession 0001664710-26-000018 (https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/kros-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/KROS/mda/fy2024/): filed 2025-02-26; accession 0001664710-25-000018 (https://www.sec.gov/Archives/edgar/data/1664710/000166471025000018/kros-20241231.htm)
- [FY 2023 MD&A](/company/KROS/mda/fy2023/): filed 2024-02-28; accession 0001664710-24-000017 (https://www.sec.gov/Archives/edgar/data/1664710/000166471024000017/kros-20231231.htm)
- [FY 2022 MD&A](/company/KROS/mda/fy2022/): filed 2023-03-03; accession 0001664710-23-000021 (https://www.sec.gov/Archives/edgar/data/1664710/000166471023000021/kros-20221231.htm)
- [FY 2021 MD&A](/company/KROS/mda/fy2021/): filed 2022-03-09; accession 0001664710-22-000011 (https://www.sec.gov/Archives/edgar/data/1664710/000166471022000011/kros-20211231.htm)

Back to /company/KROS/